 CAMBRIDGE, Mass., June 16, 2021 GLOBE NEWSWIRE -- Evelo Biosciences, Inc. Nasdaq: EVLO, a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that on June 14, 2021, Mark Plinio commenced his services as Evelos Chief Commercial Officer. In connection with the commencement of Mr. Plinios employment, the Company issued to Mr. Plinio an option to purchase 250,000 shares of the Companys common stock with a per share exercise price of 16.34, the closing trading price of the Companys common stock on the Nasdaq Global Select Market on June 14, 2021. The stock option was granted pursuant to the Companys 2021 Employment Inducement Award Plan and was approved by the Companys Board of Directors. The stock option vests subject to Mr. Plinios continued service to the Company through the applicable vesting dates 25 on June 14, 2022 and the remaining 75 in 36 substantially equal monthly installments over the three years thereafter and has a ten-year term. The stock option was granted under Rule 5635c4 of the Nasdaq Listing Rules as an inducement material to Mr. Plinios entering into employment with the Company. 